Voyager Therapeutics (NASDAQ: VYGR) net income
Voyager Therapeutics reported a net loss of $119.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $65.0m. Earnings per share were −$2.04.
Voyager Therapeutics's best year of the last 10 was fiscal 2023. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$119.7m | — | −296.5% | −$2.04 |
| 2024 | −$65.0m | −149.1% | −81.3% | −$1.13 |
| 2023 | $132.3m | — | 52.9% | $3.08 |
| 2022 | −$46.4m | — | −113.4% | −$1.21 |
| 2021 | −$71.2m | −293.8% | −190.3% | −$1.89 |
| 2020 | $36.7m | — | 21.5% | $0.99 |
| 2019 | −$43.6m | — | −41.8% | −$1.21 |
| 2018 | −$88.3m | — | −1,158.8% | −$2.75 |
| 2017 | −$70.7m | — | −697.6% | — |
| 2016 | −$40.2m | — | −282.7% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Voyager Therapeutics net income compared with its sector
By net income for its latest fiscal year, Voyager Therapeutics ranks 354th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Voyager Therapeutics, −296.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 352nd | Korro Bio | −$117.3m | −1,834.5% |
| 353rd | Savara | −$118.8m | — |
| 354th | Voyager Therapeutics | −$119.7m | −296.5% |
| 355th | TYRA Biosciences | −$119.9m | — |
| 356th | Acumen Pharmaceuticals | −$121.3m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Voyager Therapeutics
- How much did Voyager Therapeutics earn in fiscal 2025?
- Voyager Therapeutics reported a net loss of $119.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $65.0m.
- What are the earnings per share of Voyager Therapeutics?
- They were −$2.04 in fiscal 2025, compared with −$1.13 in fiscal 2024.
- What was the most profitable year for Voyager Therapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $132.3m.
- Where does Voyager Therapeutics rank in its sector by net income?
- It ranks 354th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Voyager Therapeutics come from?
- From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Voyager Therapeutics: the Voyager Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.